- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human epidermal growth factor receptor 2-positive (HER2+) locally advanced, inflammatory or early stage breast cancer
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Pertuzumab – March 2025
Pertuzumab; Solution for I.V. infusion 420 mg in 14 mL; Perjeta®
Last updated
12 March 2025